Suetaz

CHICAGO--(BUSINESS WIRE)--Aug. 13, 2004--The Pharmaceutical Press, the publications division of the Royal Pharmaceutical Society of Great Britain, with offices in London and Chicago, has published the first edition of The Medicinal Uses of Cannabis and Cannabinoids.

The publication is an authoritative review of the development of cannabis-based medicines and their applications in a wide range of therapeutic areas. It has been edited by Dr Geoffrey W Guy (Executive Chairman, GW Pharmaceuticals), Dr Philip J Robson (Senior Research Fellow, Department of Psychiatry, Oxford University and Medical Director, GW Pharmaceuticals) and Dr Brian A Whittle (Scientific Director, GW Pharmaceuticals).

The publication focuses on the research, development and clinical trial results of the cannabis-based medicinal extract (CBME) Sativex for the relief of chronic pain in MS sufferers, currently under review by the MHRA for registration. It also covers a broad spectrum of subjects including the history of cannabis use, its growth and morphology, the discovery and pharmacology of cannabinoid receptors in mammalian tissues, the development and use of synthetic cannabinoids, and the legal and forensic aspects of cannabis within the international community.

Further chapters explore the research into the basic science of cannabis and cannabinoids and highlight promising applications of CBMEs in the treatment of epilepsy, schizophrenia, bladder dysfunction and as broad-spectrum relief agents in patients with AIDS or cancer.

Professor Tony Moffat, the Society's Chief Scientist, said: "This publication demonstrates the scientific credentials of cannabis and cannabinoids as medicines. It is hoped that the evidence presented will help to change the attitude of health professionals towards cannabis-based medicines and enable the international legislative change required to allow further collaborative research into prescription medicines."

For further information and bulk sales opportunities, please contact 847-543-1708, pharmpress@ameritech.net or visit www.pharmpress.com. For orders, please contact 800-538-1287. The cost of the publication is $59.95.


Contact:
Pharmaceutical Press
Kevin Tuley, 847-543-1708
North American Marketing & Sales Manager
kevin_tuley@ameritech.net
or
Doug Purington, 847-543-1708
Office Coordinator
pharmpress@ameritech.net

[Suetaznote: Isn't it amazing the ways that people involved with pharmaceuticals seem to be able to make money off of the illegality of marijuana? Why would they want it legalized? They're probably making more money with it illegal than they would if it were legal. Create a new pill then sell a publication that gratifies it and make money off the pills and the publication all while the plant being used is illegal for everyone but the pharmaceutical companies to use. Why do our governments think pills are better than plants?]

__________________